Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio - sources
Reuters
Published Mar 15, 2021 20:48
By Pamela Barbaglia and Arno Schuetze
(Reuters) - U.S. drugmaker AbbVie Inc (NYSE:ABBV) is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan (NYSE:AGN) Plc, sources familiar with the matter told Reuters.
The move revives a process to sell the business, which makes Lo Loestrin Fe birth control pill, that Allergan started in 2018 only to ditch five months before being acquired by AbbVie in 2019.
AbbVie is working with investment bank Morgan Stanley (NYSE:MS) on an auction process that has attracted interest from private equity firms including CVC Capital Partners, said the sources speaking on condition of anonymity.
The portfolio generates 12-month earnings before interest, taxes, depreciation and amortization (EBITDA) of roughly $500 million, the sources added.
AbbVie and CVC declined to comment while Morgan Stanley was not immediately available for comment.
AbbVie has been relying heavily on its blockbuster psoriasis and rheumatoid arthritis drug Humira to drive up sales and beat revenue forecasts.
But with Humira's U.S. patent protection expiring in 2023, AbbVie needs to pay down some $143.7 billion of debt amassed through the Allergan purchase in order to focus on new investments.
The sources said CVC could use the AbbVie division to bulk up its portfolio company Theramex, formed in 2018 through its acquisition of the international women's health assets of Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) Ltd.
London-based Theramex, led by Chief Executive Robert Stewart, makes birth control pills Zoely and Seasonique as well as osteoporosis drug Actonel.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.